Log In
BCIQ
Print this Print this
 

biosimilar rituximab (GP2013)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBiosimilar of rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/25/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today